HOXA9 and ovarian carcinoma: Simultaneous methylation of SOX1+HOXA9 exhibited positivity for methylation in 75.0% (15/20) of stage I/II, 85.2% (46/54) of stage III, and 81.8% (9/11) of stage IV of ovarian cancer.